Standards for the care of people with cystic fibrosis; establishing and maintaining health
Copyright © 2023. Published by Elsevier B.V..
This is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on establishing and maintaining health. The guidance is produced using an evidence-based framework and with wide stakeholder engagement, including people from the CF community. Authors provided a narrative description of their topic and statements, which were more directive. These statements were reviewed by a Delphi exercise, achieving good levels of agreement from a wide group for all statements. This guidance reinforces the importance of a multi-disciplinary CF team, but also describes developing models of care including virtual consultations. The framework for health is reinforced, including the need for a physically active lifestyle and the strict avoidance of all recreational inhalations, including e-cigarettes. Progress with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy is reviewed, including emerging adverse events and advice for dose reduction and interruption. This paper contains guidance that is pertinent to all people with CF regardless of age and eligibility for and access to modulator therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 23(2024), 1 vom: 20. Jan., Seite 12-28 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
126880-72-6 |
|---|
| Anmerkungen: |
Date Completed 20.03.2024 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcf.2023.12.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366199188 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366199188 | ||
| 003 | DE-627 | ||
| 005 | 20240320233823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcf.2023.12.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM366199188 | ||
| 035 | |a (NLM)38129255 | ||
| 035 | |a (PII)S1569-1993(23)01727-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Southern, Kevin W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Standards for the care of people with cystic fibrosis; establishing and maintaining health |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a This is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on establishing and maintaining health. The guidance is produced using an evidence-based framework and with wide stakeholder engagement, including people from the CF community. Authors provided a narrative description of their topic and statements, which were more directive. These statements were reviewed by a Delphi exercise, achieving good levels of agreement from a wide group for all statements. This guidance reinforces the importance of a multi-disciplinary CF team, but also describes developing models of care including virtual consultations. The framework for health is reinforced, including the need for a physically active lifestyle and the strict avoidance of all recreational inhalations, including e-cigarettes. Progress with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy is reviewed, including emerging adverse events and advice for dose reduction and interruption. This paper contains guidance that is pertinent to all people with CF regardless of age and eligibility for and access to modulator therapy | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a ECFS | |
| 650 | 4 | |a Guidance | |
| 650 | 4 | |a Health | |
| 650 | 4 | |a Standards | |
| 650 | 7 | |a Cystic Fibrosis Transmembrane Conductance Regulator |2 NLM | |
| 650 | 7 | |a 126880-72-6 |2 NLM | |
| 650 | 7 | |a Respiratory System Agents |2 NLM | |
| 700 | 1 | |a Addy, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Scott C |e verfasserin |4 aut | |
| 700 | 1 | |a Bevan, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Borawska, Urzula |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Burgel, Pierre-Régis |e verfasserin |4 aut | |
| 700 | 1 | |a Button, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Castellani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Chansard, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Chilvers, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Gwyneth |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Jane C |e verfasserin |4 aut | |
| 700 | 1 | |a De Boeck, Kris |e verfasserin |4 aut | |
| 700 | 1 | |a Declercq, Dimitri |e verfasserin |4 aut | |
| 700 | 1 | |a Doumit, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Drevinek, Pavel |e verfasserin |4 aut | |
| 700 | 1 | |a Fajac, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Gartner, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Georgiopoulos, Anna M |e verfasserin |4 aut | |
| 700 | 1 | |a Gursli, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gramegna, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Carina Me |e verfasserin |4 aut | |
| 700 | 1 | |a Hug, Martin J |e verfasserin |4 aut | |
| 700 | 1 | |a Lammertyn, Elise |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Edwina Eddie C |e verfasserin |4 aut | |
| 700 | 1 | |a Langley, Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer-Hamblett, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Peter G |e verfasserin |4 aut | |
| 700 | 1 | |a Mielus, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Morrison, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Munck, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Plant, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a Ploeger, Maarten |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Dominique Pougheon |e verfasserin |4 aut | |
| 700 | 1 | |a Pressler, Tacjana |e verfasserin |4 aut | |
| 700 | 1 | |a Quon, Bradley S |e verfasserin |4 aut | |
| 700 | 1 | |a Radtke, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Saynor, Zoe L |e verfasserin |4 aut | |
| 700 | 1 | |a Shufer, Ilan |e verfasserin |4 aut | |
| 700 | 1 | |a Smyth, Alan R |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a van Koningsbruggen-Rietschel, Silke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society |d 2002 |g 23(2024), 1 vom: 20. Jan., Seite 12-28 |w (DE-627)NLM15136754X |x 1873-5010 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:12-28 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcf.2023.12.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 20 |c 01 |h 12-28 | ||